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Abstract
Background: Disturbed cellular cholesterol homeostasis may lead to accumulation of cholesterol
in human atheroma plaques. Cellular cholesterol homeostasis is controlled by the sterol regulatory
element-binding transcription factor 2 (SREBF-2) and the SREBF cleavage-activating protein
(SCAP). We investigated whole genome expression in a series of human atherosclerotic samples
from different vascular territories and studied whether the non-synonymous coding variants in the
interacting domains of two genes, SREBF-2 1784G>C (rs2228314) and SCAP 2386A>G, are related
to the progression of coronary atherosclerosis and the risk of pre-hospital sudden cardiac death
(SCD).
Methods: Whole genome expression profiling was completed in twenty vascular samples from
carotid, aortic and femoral atherosclerotic plaques and six control samples from internal mammary
arteries. Three hundred sudden pre-hospital deaths of middle-aged (33–69 years) Caucasian
Finnish men were subjected to detailed autopsy in the Helsinki Sudden Death Study. Coronary
narrowing and areas of coronary wall covered with fatty streaks or fibrotic, calcified or complicated
lesions were measured and related to the SREBF-2 and SCAP genotypes.
Results: Whole genome expression profiling showed a significant (p = 0.02) down-regulation of
SREBF-2 in atherosclerotic carotid plaques (types IV-V), but not in the aorta or femoral arteries (p
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Thrombosis Journal 2008, 6:17 http://www.thrombosisjournal.com/content/6/1/17= NS for both), as compared with the histologically confirmed non-atherosclerotic tissues. In
logistic regression analysis, a significant interaction between the SREBF-2 1784G>C and the SCAP
2386A>G genotype was observed on the risk of SCD (p = 0.046). Men with the SREBF-2 C allele
and the SCAP G allele had a significantly increased risk of SCD (OR 2.68, 95% CI 1.07–6.71),
compared to SCAP AA homologous subjects carrying the SREBF-2 C allele. Furthermore, similar
trends for having complicated lesions and for the occurrence of thrombosis were found, although
the results were not statistically significant.
Conclusion: The results suggest that the allelic variants (SREBF-2 1784G>C and SCAP 2386A>G)
in the cholesterol homeostasis regulating SREBF-SCAP pathway may contribute to SCD in early
middle-aged men.
Background
Cholesterol is an essential component of cellular mem-
branes. Cellular cholesterol homeostasis is controlled by
sterol regulatory element-binding transcription factors
(SREBFs), which are transcription factors that modulate
the transcription of genes involved in lipid and choles-
terol metabolism. In sterol-depleted cells, SREBF cleavage
activating protein (SCAP) forms a complex with SREBF
and assists in its transportation to the Golgi apparatus
where it can be processed by two specific proteases and
then release the amino-terminal transcription-activation
domain of the SREBF. The active form of SREBF can then
travel to the nucleus where it binds to the promoters of
target genes [1]. The SREBFs consist of three different
SREBF isoforms, SREBF-1a, SREBF-1c and SREBF-2. They
are produced by two genes, with SREBF-1a and -1c tran-
scribed from a single gene by alternative promoter use and
splicing, and SREBF-2 from a separate gene [2]. There is
considerable evidence suggesting that SREBF-2 is closely
associated with cholesterol metabolism, while SREBF-1 is
more associated with the control of genes involved in fatty
acid metabolism [3,4].
As regulatory factors of cellular cholesterol metabolism,
SREBF-2 as well as SCAP together with low-density lipo-
protein receptor and 3-hydroxy-3-methylglutaryl coen-
zyme A reductase are assumed to be down-regulated in
human atherosclerotic plaques due to the cholesterol
overload. However, we were able to find only one publi-
cation quantitatively comparing the expression of SREBF-
2 mRNA in human atherosclerotic plaques with nearby
macroscopically intact carotid artery tissue [5]. This anal-
ysis revealed no differences in the expression of low-den-
sity lipoprotein receptor, 3-hydroxy-3-methylglutaryl
coenzyme A reductase or SREBF-2 between the plaque and
the control tissues with no histological classification of
atherosclerosis [5].
Given the central role of the SREBF-SCAP pathway in the
regulation of cholesterol, the variation in the SREBF-2 and
SCAP locus might affect the progression of atherosclero-
sis. SREBF-2 is encoded by a gene (sterol regulatory ele-
ment binding transcription factor, SREBF-2) on human
chromosome 22q13 [2], which is composed of 19 exons
[6]. A common polymorphism is located in exon 10,
namely the 1784G>C (rs2228314) transversion resulting
in the substitution of a glycine by an alanine at amino acid
595 of the SREBF-2 protein. This polymorphism was
reported to be associated with serum levels of total choles-
terol in hypercholesterolemic subjects from Switzerland
and Israel [7] and from northern China [8]. This polymor-
phism was also associated with the intima-media thick-
ness in French asymptomatic men [9].
SCAP is a membrane-bound protein containing two dis-
tinct domains: a sterol-sensing domain which serves as a
cell cholesterol sensor and a carboxy-terminal domain
with multiple WD repeats which mediates protein-protein
interaction [10]. The human SCAP gene is located at chro-
mosome 3p21.3 with 23 exons [11]. The SCAP gene has
an exonic polymorphism located at exon 16 (A-to-G tran-
sition, 2386A>G) and leading to isoleucine-to-valine sub-
stitution (I796V) [12]. This polymorphism has been
reported to be a significant predictor of the response of
total cholesterol and triglyceride levels to simvastatin
treatment [13], but not to fluvastatin [14] and pravastatin
therapy [15].
There are two publications about the interaction effect of
SREBF-2 1784G>C and SCAP 2386A>G at present. The
combination of SREBF-2 1784G>C and SCAP 2386A>G
has an effect on LDL cholesterol levels among familial
hypercholesterolemia females [16]. Interestingly, the
SCAP 2386A>G genotypes were found to modify the asso-
ciation between SREBF-2 1784G>C and myocardial inf-
arction (MI) in men [17].
Therefore, we investigated the expression of SREBF-2 and
SCAP in human atherosclerotic tissues and compared
them in different arterial beds, i.e. the carotid, aorta and
femoral region, to methodologically accurately confirmed
normal arterial tissue. We also related the variations
1784G>C and 2386A>G in the interacting domains of the
SREBF-2 and SCAP genes to the areas of the different typesPage 2 of 8
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the risk of sudden cardiac death (SCD) and acute myocar-
dial infarction (AMI) in an autopsy series of 300 Finnish
men included in the Helsinki Sudden Death Study
(HSDS).
Methods
Vascular samples
The vascular sample series consists of 20 samples from the
carotid artery, the femoral artery and the abdominal aorta
(15 males, 5 females, aged 69 ± 11 years). Six control sam-
ples were taken from internal mammary arteries (4 males,
2 females, aged 66 ± 11 years). The study was approved by
the Ethics Committee of Tampere University Hospital,
and the study subjects gave their informed consent. The
samples were taken from patients subjected to open vas-
cular surgical procedures at the Division of Vascular Sur-
gery, Tampere University Hospital. The vascular samples
were histologically classified according to the recommen-
dations of the American Heart Association [18].
RNA isolation and genome-wide expression analysis
The fresh tissue samples were soaked in RNALater solu-
tion (Ambion Inc., Austin, TX, USA) and isolated with Tri-
zol reagent (Intitrogen, Carlsbad, CA, USA) and the
RNAEasy Kit (Qiagen, Valencia, CA, USA). The concentra-
tion and quality of RNA were evaluated spectrophotomet-
rically with Agilent (BioPhotometer, Eppendorf,
Wesseling-Berzdorf, Germany). Over 23,000 known
genes and gene candidates were analyzed using Sentrix
Human-8 Expression BeadChips, according to manufac-
turer's instructions (Illumina, San Diego, CA, USA). In
brief, 200 ng aliquot of total RNA from each sample was
amplified to cDNA. In vitro transcription reaction of
cDNA to cRNA was performed overnight (14 h) including
biotin-11-dUTP for labeling the cRNA product. Each sam-
ple cRNA (1500 ng) was hybridized to Illumina's Sentrix
Human-8 Expression BeadChip arrays. Hybridized bioti-
nylated cRNA was detected with 1 μg/ml Cyanine3-
streptavidine (Amersham Biosciences, Pistacataway, NJ,
USA). BeadChips were scanned with the Illumina BeadAr-
ray Reader. The method has been described in more detail
previously [19].
Bioinformatics analysis of homology recognition of protein 
sequences and two SNPs
Sequence homologues for the SCAP and SREBF-2 proteins
were obtained by PSI-BLAST [20]. The bioinformatics
analysis of the mutations was performed at the sequence
level as described by Thusberg et al. [21]. The secondary
structures were predicted by the programmes PSIPRED
[22] and PHD [23].
Helsinki Sudden Death Autopsy Study
The HSDS was launched to study the lifestyle and genetic
factors predisposing to sudden death in Finnish middle-
aged men who lived in Helsinki and its surroundings. The
present autopsy series was collected during 1991–1992 (n
= 300) at the Department of Forensic Medicine, University
of Helsinki. The cause of death was cardiac in 39% (n =
117), other diseases in 21% (n = 63) and suicides or acci-
dents in 40% (n = 120) of the subjects. The study was
approved by the Ethics Committee of the Department of
Forensic Medicine, University of Helsinki.
Measurement of the area of atherosclerosis by computer-
assisted morphometry
At autopsy, the proximal parts of the left anterior descend-
ing coronary artery (LAD), right coronary artery (RCA)
and left circumflex coronary artery (LCX) were collected
for analysis. The definition of atherosclerotic lesions was
based on the protocols of two international studies: the
International Atherosclerosis Project, Standard Operating
Protocol 1962 [24] and the WHO Study Group in Europe
[25]. The areas of coronary artery wall covered by fatty
streaks as well as fibrous and complicated lesions were
measured with a computer-assisted planimetric tech-
nique. The details have been described in a previous pub-
lication [26]. The areas of coronary artery calcification
were measured by examining the radiograph taken from
the dissected coronary arteries. The mean proportional
area of each particular atherosclerotic change in the three
coronary arteries was used for statistical analysis. Of the
series of 300 men, arterial samples for the measurements
of atherosclerotic changes were available from 290 men
for the analysis of three coronary arteries.
Measuring the percentage of stenosis in silicone rubber 
casts of the coronary arteries
At autopsy, coronary angiography was performed using
vulcanising liquid silicone rubber [27]. The proximal,
middle and distal stenosis of the main trunks of the three
main epicardial coronary arteries (LAD, LCX and RCA)
were measured from the rubber cast model. The stenosis
percentage was obtained by dividing the diameter (milli-
metres) of the greatest stenosis by the diameter of the
nearest proximal undamaged part of the cast model of the
artery, resulting in nine measurements of the degree of ste-
nosis for each individual. The most severe stenosis was
used to define the extent of coronary narrowing for each
individual. These measurements were available for 279
men.
Determining the MI phenotype at autopsy
Coronary thrombosis and myocardial infarction were
recorded at autopsy, and the presence of MI was con-
firmed by nitro blue tetrazolium staining and by a histo-
logical examination of the myocardium. The presence ofPage 3 of 8
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AMI. Thrombosis was defined by a reddish clot attached
to the coronary wall if the clot could not be detached with
saline flushing.
Collection of risk factor data
A spouse, a relative or a close friend of the deceased could
be interviewed in 147 cases. The questionnaire included a
review of risk factors including hypertension, diabetes,
past and recent smoking, drinking habits and previous ill-
nesses. On the basis of these interviews, men were classi-
fied as smokers or non-smokers. Ex-smokers were
included in the category of smokers for statistical analysis.
Average daily alcohol consumption of the deceased was
calculated based on the information given by the persons
interviewed. Based on questions concerning previous ill-
nesses, 50 men had suffered from hypertension and 22
from diabetes.
DNA extraction and genotyping
DNA was extracted from frozen cardiac muscle samples.
The SCAP 2386A>G genotyping was based on PCR ampli-
fication, restriction enzyme analysis and DNA electro-
phoresis. The DNA samples were amplified by PCR, using
the primers 5'-TTGTGCTGCGCGGCCACCTCA-3' and 5'-
AGGAGGAAAGGGCAGCCGCAC-3'. PCR was performed
in a volume of 50 μl. Cycle conditions were 94°C for 4
min, then 28 cycles of 94°C for 1 min, 64°C for 1 min
and 72°C for 1 min, with a final extension step of 5 min
at 72°C in a PTC-225 thermal cycler (MJ research, Massa-
chusetts, USA). 10% DMSO was included in PCR reaction.
The PCR-amplified DNA fragment was incubated for 16
hours with 10 U of MslI (New England Biolabs). Electro-
phoresis was performed on a 3% agarose gel containing
ethidium bromide. Genotype information was obtained
for 269 men.
For the SREBF-2 1784G>C genotyping, DNA samples
were genotyped by employing the 5' nuclease assay for
allelic discrimination, with the ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA).
PCR reaction containing genomic DNA, 2 × TaqMan uni-
versal PCR Master Mix, 900 nM of each primer and 200
nM of each probe was performed in 96-well plates accord-
ing to standard protocol in a total volume of 25 μl. After
cycling, end-point fluorescence was measured, and geno-
type calling was carried out by the allelic discrimination
analysis module. Genotyping was successful in 271 men.
As a means of quality control for genotyping, empty con-
trols and random duplicate samples were used.
Statistical analysis
The non-parametric Mann-Whitney U test was used for
comparison of gene expression between atherosclerotic
and control tissues. Complete data on SREBF-2 and SCAP
genotypes as well as autopsy data were available in 247
cases; this autopsy cohort constituted the final study pop-
ulation. Data analysis for continuous variables was based
on analysis of variance (ANOVA) and analysis of covari-
ance (ANCOVA), in which the possible confounding
effects of age, body mass index (BMI) and hypertension
were taken into account by including them in the model
as covariates. Categorical variables were compared with
the χ2 test. Fisher's exact test was used to test the genotype
frequencies under Hardy-Weinberg equilibrium. Non-
normally distributed data concerning the areas of athero-
sclerotic changes were analysed after square-root transfor-
mation, but the results are displayed as crude data. We
analysed the interaction between SREBF-2 1784G>C and
SCAP 2386A>G genotypes using logistic regression. Logis-
tic regression analysis was also used to determine odds
ratios for SCD according to SREBF-2 1784G>C and SCAP
2386A>G genotype groups. The statistical analysis was
performed by means of SPSS Version 14.0.1 (SPSS Inc.,
Chicago, USA). The level of significance was set at p <
0.05.
Results
SREBF-2 and SCAP expression in atherosclerotic tissue
The SREBF-2 gene expression was reduced 1.5-, 1.1- and
1.3-fold in the carotid artery (n = 9), aorta (n = 7) and
femoral artery (n = 4), respectively. Only the SREBF-2
expression level in the carotid artery was significantly
lower in atherosclerotic tissue than in control tissue (n =
6, p = 0.02 by Mann-Whitney U test). The similar trend of
the SCAP gene expression was also found in three arteries,
although it did not reach statistically significant. When all
atherosclerotic arterial samples (type IV-V plaques) were
pooled, there were no differences in the mean gene
expression of either SREBF-2 or SCAP in atherosclerotic
tissue as compared with histologically confirmed healthy
control samples (type 0).
Bioinformatics analysis
The search by PSI-BLAST yielded 64 homologue
sequences for SCAP and 62 sequences for SREBF-2, after
the removal of duplicates and hypothetical proteins.
The mutation position in SCAP is physicochemically con-
served (the conserved property is hydrophobicity), and
the frequencies of the physiochemically similar amino
acids (V, L and I) are approximately equal. The disease-
causing mutation studied here (I796V) is thus a conserva-
tive substitution. The mutation position in SREBF-2 is not
at all conserved, and the following amino acids are found
at this position: Y, V, T, S, R, Q, L, K, G, E and A. Q and E
are the amino acids with the highest frequency of occur-
rence in the alignment. The mutations do not seem to
have a direct structural effect on the proteins.Page 4 of 8
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subjects and their association with the area of different 
atherosclerotic changes
Of all the 247 men with genotype and autopsy data avail-
able, the allele frequencies did not differ significantly
between the subpopulations with or without interview
data. In addition to the SREBF-2 and SCAP genotypes as
well as autopsy data, full risk factor data was available in
124 cases. The distributions of SREBF-2 1784G>C and
SCAP 2386A>G genotypes were in accordance with the
Hardy-Weinberg equilibrium (Fisher's exact test p = 0.22
and p = 0.06, respectively). The characteristics of the study
subjects according to SREBF-2 and SCAP genotype are
shown in Table 1. There were no differences in any char-
acteristics according to SREBF-2 genotype. Only SCAP
2386A>G GG carriers had a higher prevalence of hyper-
tension than subjects with other genotypes. No significant
differences existed in the occurrence of SCD, AMI and
thrombosis between the SREBF-2 or SCAP genotypes
(Table 1).
The association between the SREBF-2 1784G>C and SCAP
2386A>G genotypes and the area of different atheroscle-
rotic changes are shown in Table 2. We found borderline
significant associations between the SCAP 2386A>G gen-
otypes and the mean percentage area of complicated
lesions as well as between the SREBF-2 1784G>C geno-
types and fatty streak area (Table 2). These results
remained when ANCOVA was employed after adjustment
for age, BMI and hypertension.
The interaction of SREBF-2 and SCAP genotypes on the 
risk of SCD
A significant interaction effect of SREBF-2 and SCAP gen-
otypes was found on the risk of SCD (p = 0.046). The per-
centage of men with the SREBF-2 C allele in combination
with the SCAP G allele among SCD victims tended to be
higher than that found in the non-SCD group (34.7% vs.
26.3%). Carriage of the SREBF-2 C allele and the SCAP G
allele was associated (OR 2.68, 95% confidence interval
[CI] 1.07–6.71, p = 0.035) with an increased risk of SCD
when compared with subjects carrying the SREBF-2 C
allele and those with the SCAP AA genotype (Table 3). The
significant difference remained after adjustment for age,
BMI and hypertension.
Furthermore, we found a similar trend suggesting that
there were more carriers of the combination SREBF-2 C
allele and SCAP G allele among men with AMI, compli-
cated lesions and coronary thrombosis than among those
who did not suffer from these ailments but here the results
were not statistically significant (Table 4). Carriage of the
SREBF-2 C allele and the SCAP G allele was associated
(OR 2.4, p = 0.06) with an increased risk of having com-
plicated lesions when compared with subjects carrying the
SREBF-2 C allele and the SCAP AA genotype. The combi-
nation of the SREBF-2 C allele and the SCAP G allele was
present in 8 of the 20 men (40%) with coronary thrombo-
sis, whereas the SREBF-2 C allele in combination with the
SCAP AA genotype was present in 2 of the 20 men (10%)
with coronary thrombosis (Table 4). There were also more
carriers of the SREBF-2 C allele in combination with the
SCAP G allele among men with AMI than among men
who had died of a non-AMI (Table 4).
Discussion
We showed that SREBF-2 expression in the carotid artery
was decreased in atherosclerotic tissue as compared to his-
tologically confirmed healthy control tissue. The similar
trend of SCAP gene expression was also found, although
there was no statistically significant difference between
the atherosclerotic tissue and control samples. In the
present study, the SREBF-2 1784G>C or SCAP 2386A>G
genotypes were also not associated with SCD alone. How-
ever, we found that the SREBF-2 1784G>C and SCAP
2386A>G genotypes have a significant interaction on the
risk of SCD. The combination of the SREBF-2 C allele and
the SCAP G allele was associated with an increased risk of
Table 1: Characteristics of the study subjects by SCAP and SREBF-2 genotype
SCAP SREBF-2
AA GA GG P value GG GC CC P value
Number of subjects 85 132 30 140 97 10
Age (years) 51.9 ± 9.5 51.6 ± 9.4 55.6 ± 10.3 0.114 51.9 ± 9.3 52.9 ± 9.9 49.1 ± 11.0 0.445
BMI (kg/m2) 25.4 ± 5.1 25.4 ± 4.9 24.3 ± 4.1 0.497 25.2 ± 4.9 25.3 ± 4.7 25.1 ± 6.3 0.979
Alcohol consumption (g/day) 101.5 ± 116.4 106.5 ± 106.6 74.0 ± 68.2 0.549 110. 8 ± 110.9 91.9 ± 100.4 42.7 ± 84.2 0.340
Smoking 35 (72.9) 64 (80.0) 13 (92.9) 0.256 62 (82.7) 45 (72.6) 5 (100.0) 0.177
Hypertension 6 (13.6) 31 (46.3) 5 (38.5) 0.002 23 (32.9) 18 (36.0) 1 (25.0) 0.872
Diabetes 6 (13.6) 11 (16.4) 2 (15.4) 0.924 13 (18.6) 6 (12.0) 0 (0.0) 0.423
AMI 7 (8.2) 17 (12.9) 4 (13.3) 0.537 13 (9.3) 14 (14.4) 1 (10.0) 0.466
Thrombus 4 (4.7) 14 (10.6) 2 (6.7) 0.285 10 (7.1) 9 (9.3) 1 (10.0) 0.818
SCD 29 (34.1) 51 (38.6) 15 (50.0) 0.306 54 (38.6) 38 (39.2) 3 (30.0) 0.850
Values are mean ± SD or n (%). Abbreviations: AMI, acute myocardial infarction; BMI, body mass index; MI, myocardial infarction; SCD, sudden 
cardiac death; Analysis by ANOVA or χ2 testPage 5 of 8
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C allele and the SCAP AA genotype. Our results also sug-
gest that this association may be due to the presence of
more complicated lesions and thrombosis among the
subjects with the SREBF-2 C allele in combination with
the SCAP G allele.
Serum cholesterol is a major component in the causal
pathway of atherosclerosis, which has been verified in
familial hypercholesterolemia patients [28]. The cellular
cholesterol homeostasis is subject to a regulatory feedback
system that senses the level of cholesterol in cellular mem-
branes and modulates the transcription of genes encoding
enzymes involved in cholesterol biosynthesis and in the
uptake of plasma lipoproteins. As regulators of this cho-
lesterol metabolism, SREBF-2 and SCAP might play a role
in the progression of atherosclerosis. Our gene expression
results with human tissues are in agreement with in vivo
findings indicating that SREBF-2 is down-regulated by
hypercholesterolemia in porcine aortas [29]. In another
study, Forcheron et al. observed that the mRNA expres-
sion of SREBF-2 was unchanged in human atheroma
when compared with nearby macroscopically intact tissue
[5]. Although there was no histological evidence of
atherosclerosis in the control vessels, however, the
absence of atherosclerosis cannot be explicitly excluded,
and thus it is therefore possible that the expression of
SREBF-2 was already near-maximally suppressed, explain-
ing the results of unaltered relative gene expression.
Therefore, our results support the notion of the suppres-
sion of SREBF-2 in atherosclerotic lesions which are usu-
ally bathed in high levels of lipoproteins.
The SREBF-2 1784G>C variant is located in carboxyl-ter-
minal regulating region, which forms a complex with the
carboxyl-terminal WD repeat domain that contains SCAP
2386A>G substitution. Therefore, the domains of SREBF-
2 and SCAP that contain the SREBF-2 1784G>C and SCAP
2386A>G variation directly interact with each other. A
functional study of the SREBF-2 1784G>C variant has
shown that the SREBF-2 CC isoform results in a decreased
SREBF-2 cleavage-rate in vitro [7]. Moreover, this variant
was associated with serum total cholesterol in hypercho-
lesterolemic subjects [7,8], and carotid intima media
thickness values were higher in homozygous subjects for
the presence of the C allele [9]. However, no functional
studies of the SCAP 2386A>G variant have been carried
out. There are only several studies with conflicting results
regarding the influence of the SCAP 2386A>G variant on
lipid-lowering therapy [13-15].
Our results are in accordance with a previous study in
which the SREBF-2 C allele in combination with the SCAP
G allele was associated with an increased risk of MI in
males [17]. Our results extend the existing data, since
there is no previous evidence suggesting that the same
allelic combination of the SREBF-SCAP pathway that
alters the risk of MI is also associated with the risk of SCD.
The interaction of the SREBF-2 1784G>C and the SCAP
2386A>G variant on SCD risk observed in our study may
be partially due to an impaired formation and/or
decreased stability of the SCAP/SREBF-2 complex and to
altered interaction function, therefore altering cholesterol
metabolism in human cells. A possible explanation
through bioinformatics analysis for these two variations is
that there is a physical interaction between these amino
acids (SCAP 796 and SREBF-2 595), and this interaction is
prevented by the variations, impairing the formation of
the SCAP/SREBF-2 complex. However, because 3D struc-
tures of these proteins are not available, this must be inter-
preted with caution. According to the secondary structure
predictions, the 1784G>C position in SREBF-2 is in α-
Table 2: Mean percent area of different types of atherosclerotic lesions in coronary arteries by SCAP and SREBF-2 genotype
SCAP SREBF-2
AA GA GG P value GG GC CC P value
85 132 30 140 97 10
Fatty streaks 5.75 ± 4.87 6.12 ± 5.14 4.90 ± 4.19 0.463 5.51 ± 4.21 6.60 ± 5.88 3.17 ± 2.93 0.060
Fibrotic 3.06 ± 3.29 3.40 ± 3.77 2.95 ± 3.46 0.711 3.05 ± 3.44 3.61 ± 3.82 2.01 ± 2.45 0.268
Complicated 0.68 ± 1.95 1.64 ± 4.12 1.17 ± 2.38 0.053 1.26 ± 3.83 1.26 ± 2.66 1.10 ± 1.83 0.989
Calcification 2.08 ± 3.23 2.59 ± 4.97 3.06 ± 5.68 0.542 2.63 ± 4.73 2.38 ± 4.43 1.10 ± 2.46 0.572
Stenosis 36.99 ± 23.23 37.08 ± 21.12 38.36 ± 21.76 0.956 36.10 ± 22.26 39.14 ± 21.20 34.47 ± 22.92 0.550
Values are mean ± SD. Analysis by ANOVA.
Table 3: Joint association between SCAP and SREBF-2 genotypes 
and SCD risk
Genotype Number of subjects OR (95% CI)
SCAP SREBF-2 SCD Non-SCD
AA GC+CC 8 26 1.00 (Reference)
GG 21 30 2.28 (0.86–5.99)
AG+GG GC+CC 33 40 2.68 (1.07–6.71)
GG 33 56 1.92 (0.78–4.72)
Abbreviation: OR, odds ratio; SCD, sudden cardiac death.Page 6 of 8
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the 2386A>G position in SCAP, but for a β-strand. The
mutant sites are therefore on the ordered secondary struc-
tural elements and possibly on the surface of the proteins,
which is supported by many predictors when the amino
acid substitutions are considered to be tolerated. How-
ever, our study is epidemiological in nature and still need
for empirical in silico proof for the interaction.
The limitations of our study include the two distinct sam-
ple materials we used: The vascular samples collected
from elective patients subjected to open vascular surgical
procedures were used for the SREBF-2 and SCAP mRNA
expression study, and the HSDS samples were used for the
association study between SREBF-2 1784G>C as well as
SCAP 2386A>G and coronary atherosclerosis. The form of
atherosclerosis in these two materials might be different,
because they were collected from different vascular territo-
ries with different local haemodynamic conditions. Other
limitations are related to the nature of autopsy studies:
since the subjects had died suddenly and most of them
had not seen a doctor nor had any blood samples taken
prior to their death, we were unable to determine the lipid
levels. We also did not measure the cholesterol and apol-
ipoprotein levels in post-mortem samples. Furthermore,
this study only enrolled Finnish men. We cannot ascertain
whether the interactive effect of the SREBF-2 1784G>C
and the SCAP 2386A>G variant would extend to other
populations or women, as well.
In summary, we demonstrated a down-regulated expres-
sion of SREBF-2 in atherosclerotic carotid plaques as com-
pared with histologically confirmed normal tissues. We
also showed a gene-gene interaction between the SREBF-
2 1784G>C and the SCAP 2386A>G genotypes on the risk
of developing SCD in middle-aged men. We conclude that
SREBF-2 and SCAP may be implicated in the progression
of atherosclerosis and the risk of developing SCD. Future
structure-function and replication studies with large sam-
ples are required to improve the understanding of how
SREBF-2 and SCAP function, in addition to explaining the
results presented here.
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